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The role of endomyocardial biopsy (EMB) in the diagnosisand treatment of adult and pediatric cardiovascular dis-
ease remains controversial, and the practice varies widely
even among cardiovascular centers of excellence. A need for
EMB exists because specific myocardial disorders that have
unique prognoses and treatment are seldom diagnosed by
noninvasive testing (1). Informed clinical decision making
that weighs the risks of EMB against the incremental diag-
nostic, prognostic, and therapeutic value of the procedure is
especially challenging for nonspecialists because the relevant
published literature is usually cited according to specific
cardiac diseases, which are only diagnosed after EMB. To
define the current role of EMB in the management of
cardiovascular disease, a multidisciplinary group of experts in
cardiomyopathies and cardiovascular pathology was con-
vened by the American Heart Association (AHA), the Amer-
ican College of Cardiology (ACC), and the European Society
of Cardiology (ESC). The present Writing Group was charged
with reviewing the published literature on the role of EMB in
cardiovascular diseases, summarizing this information, and mak-
ing useful recommendations for clinical practice with classifica-
tions of recommendations and levels of evidence.
The Writing Group identified 14 clinical scenarios in
which the incremental diagnostic, prognostic, and therapeutic
value of EMB could be estimated and compared with the
procedural risks. The recommendations contained in the
present joint Scientific Statement are derived from a compre-
hensive review of the published literature on specific cardio-
myopathies, arrhythmias, and cardiac tumors and are catego-
rized according to presenting clinical syndrome rather than
pathologically confirmed disease. The ultimate intent of this
document is to provide an understanding of the range of
acceptable approaches for the use of EMB while recognizing
that individual patient care decisions depend on factors not
well reflected in the published literature, such as local
availability of specialized facilities, cardiovascular pathology
expertise, and operator experience. The use of EMB in the
posttransplantation setting is beyond the scope of this document.
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The classifications of recommendations used in this docu-
ment are
● Class I: conditions for which there is evidence or there is
general agreement that a given procedure is beneficial,
useful, and effective;
● Class II: conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of a procedure or treatment;
 Class IIa: conditions for which the weight of evi-
dence/opinion is in favor of usefulness/efficacy;
 Class IIb: conditions for which usefulness/efficacy is
less well established by evidence/opinion; and
● Class III: conditions for which there is evidence and/or
general agreement that a procedure/treatment is not
useful/effective and in some cases may be harmful.
The levels of evidence are
● Level A (highest): multiple randomized clinical trials;
● Level B (intermediate): limited number of randomized
trials, nonrandomized studies, and registries; and
● Level C (lowest): primarily expert consensus.
Technique and Risks of EMB
The first nonsurgical techniques for heart biopsy were re-
ported in 1958 (2). In the 1960s the safety of heart biopsy
improved, with vascular access through the right external or
internal jugular vein, sampling of the right interventricular
septum, and designation of the heart borders by right heart
catheterization before biopsy (3). Sakakibara and Konno (4)
introduced the use of a flexible bioptome with sharpened
cusps that allowed EMB by a pinching as opposed to a cutting
technique. Caves et al (5) modified the Konno biopsy forceps
(Stanford Caves-Shulz bioptome) to allow percutaneous bi-
opsies through the right internal jugular vein with only local
anesthesia and rapid tissue removal. The reusable Stanford-
Caves bioptome and its subsequent modifications became the
standard device for EMB for approximately 2 decades (6,7).
Single-use bioptomes and sheaths allow access through the
right and left jugular or subclavian veins, right and left
femoral veins, and right and left femoral arteries and may be
associated with lower risk of pyrogen reaction and transmis-
sion of infection than reusable bioptomes.
The right internal jugular vein is the most common
percutaneous access site for right ventricular EMB in the
United States. In Germany and Italy, the femoral vein is
commonly used for percutaneous access (8). Sonographic
techniques to identify the location, size, and respirophasic
variation in size of the internal jugular vein decrease the
duration of the procedure and complications (9,10). Monitor-
ing should include electrocardiographic rhythm, blood pres-
sure, and pulse oximetry. The subclavian vein also may be
used occasionally.
The femoral artery may be used as a percutaneous access
site for left ventricular biopsy (11,12). This approach
requires insertion of a preformed sheath to maintain
arterial patency. All arterial sheaths must be maintained
under constant pressurized infusion to avoid embolic
events. Aspirin or other antiplatelet agents may be used in
addition to heparin during left heart biopsy procedures to
decrease the risk of systemic embolization. No compara-
tive studies exist on which to base a recommendation for
left versus right ventricular biopsy; however, left ventric-
ular biopsy has been used in case series to define cardio-
myopathic processes limited to the left ventricle (13).
EMB usually is performed safely under fluoroscopic guid-
ance. Fluoroscopy is generally better than 2-dimensional
echocardiography to guide EMB because it provides more
information to the operator about the course of the bioptome
and site of biopsy (14,15). The echocardiographic technique
without fluoroscopy has been used primarily to biopsy
intracardiac masses. Some operators use fluoroscopy and
echocardiography in combination to enhance entry into the
right ventricle and direction of the bioptome. Noninvasive
computed tomography (CT) or cardiac magnetic resonance
(CMR) imaging may be of value in patients scheduled for
EMB. CT scanning may be used to assess the angle of the
intraventricular septum relative to the superior vena cava
or inferior vena cava. Knowledge of this angle may lessen
the risk of inadvertent biopsy of the right ventricular free
wall during a fluoroscopically directed biopsy. In addition,
CMR detection of a focal disease process may identify the
area of the left or right ventricle that would be most likely
to demonstrate the underlying pathological process
(13,16). Three-dimensional echocardiography may en-
hance visualization and reduce the reliance on radiographic
imaging in the future (17).
The risks of EMB may be divided into those that are acute
and those that are delayed. Immediate risks of biopsy include
perforation with pericardial tamponade, ventricular or su-
praventricular arrhythmias, heart block, pneumothorax, punc-
ture of central arteries, pulmonary embolization, nerve pare-
sis, venous hematoma, damage to the tricuspid valve, and
creation of arterial venous fistula within the heart. The risks
of EMB likely vary with the experience of the operator,
clinical status of the patient, presence or absence of left
bundle-branch block, access site, and possibly bioptome. The
use of a long sheath that crosses the tricuspid valve may
decrease the risk of bioptome-induced tricuspid valve trauma.
Delayed complications include access site bleeding, damage
to the tricuspid valve, pericardial tamponade, and deep
venous thrombosis. Most complications are known from case
reports, and therefore the precise frequency of these events is
not known.
The data on EMB risks are derived from several single-
center experiences and registries that have been reported in
the literature. Fowles and Mason (18) reported an overall
complication rate of 1% in 4000 biopsies performed in
transplantation and cardiomyopathy patients, including 4 with
tamponade (0.14%), 3 pneumothorax, 3 atrial fibrillation, 1
ventricular arrhythmia, and 3 focal neurological complica-
tions (18). Olsen, in an unpublished series referenced by
Fowles and Mason (18), reported an overall complication rate
of 1.55% in 3097 cardiomyopathy patients biopsied in Eu-
rope. Sekiguchi and Take (19) reported a 1.17% complication
rate in a worldwide questionnaire of 6739 patients, including
perforation in 28 patients (0.42%) and death in 2 patients
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(0.03%). Deckers et al (20) prospectively recorded compli-
cations from 546 consecutive right heart biopsy procedures in
patients with new-onset unexplained cardiomyopathy. These
are the most reliable data in the literature (20); the compli-
cation rates of sheath insertion and biopsy procedure were
reported as 2.7% and 3.3%, as noted in Table 1.
The death rate associated with EMB is a result of perfora-
tion with pericardial tamponade (20). Patients with increased
right ventricular systolic pressures, bleeding diathesis, recent
receipt of heparin, or right ventricular enlargement seem to be
at higher risk. Echocardiography is used to confirm myocar-
dial perforation and should be done in any patient in whom
the operator believes perforation may have occurred, even
without cardiovascular collapse, before central venous access
is removed or the patient leaves the catheterization labora-
tory. Immediate pericardiocentesis and the capability to
surgically evacuate the pericardial space should be available
at centers that perform EMB.
Careful attention to technique can minimize procedural
risks. The risk of pneumothorax can be minimized by taking
a relatively high internal jugular approach and avoiding the
immediate supra-clavicular location. Patients with preexistent
left bundle-branch block may develop complete heart block
when any catheter is placed into the right ventricle and
presses against the intraventricular septum (20). If this oc-
curs, the bioptome and/or sheath must be removed, and the
patient may require temporary ventricular pacing. Rarely, the
heart block may be permanent. Lidocaine in the jugular
venous and carotid sheath may result in Horner syndrome,
vocal paresis, and, infrequently, weakness of the diaphragm.
These complications last only for the duration of the lidocaine
effect, unless permanent damage has been done by trauma
from the needle itself.
The risks of EMB depend on the clinical state of the
patient, the experience of the operator, and the availability of
expertise in cardiac pathology. If a patient with an indication
for EMB presents at a medical center where expertise in EMB
and cardiac pathology is unavailable, transfer of the patient to
a medical center with such experience should be seriously
considered. Additionally, patients with cardiogenic shock or
unstable ventricular arrhythmias may require the care of
specialists in medical and surgical management of heart
failure, including ventricular assist device placement and
potentially heart transplantation.
Analysis of EMB Tissue
EMB Processing
Samples should be obtained from 1 region of the right
ventricular septum. The number of samples obtained should
range from 5 to 10, depending on the studies to be performed,
and each sample should be 1 to 2 mm3 in size. The sample
must be handled carefully to minimize artifacts and trans-
ferred from the bioptome to fixative (10% neutral buffered
formalin) by use of a sterile needle and not with forceps
(21,22). The fixative should be at room temperature to
prevent contraction band artifacts (23).
The clinical reason for the biopsy determines how many
samples are removed and how they are fixed. In general, at
least 4 to 5 samples are submitted for light microscopic
examination, but more may be submitted for transmission
electron microscopy if the clinical question is anthracycline
cardiotoxicity (22,24,25). Transmission electron microscopy
may also be helpful for the assessment of suspected infiltra-
tive disorders such as amyloidosis, glycogen storage diseases,
lysosomal storage diseases, and occasionally viral myocardi-
tis. For transmission electron microscopy, pieces are fixed in
4% glutaraldehyde at room temperature at the time of EMB
(22). One or more pieces may be frozen for molecular studies,
immunofluorescence, or immunohistochemistry that may be
required for suspected myocarditis, storage diseases, tumor
typing, amyloid classification, or viral genome analysis (26).
Pieces of myocardium can be snap-frozen in OCT-embedding
medium and stored at 80°F for immunohistochemical or
liquid nitrogen molecular studies. Flash-freezing is suitable
for culture, polymerase chain reaction (PCR), or reverse
transcriptase PCR (rtPCR) for the identification of viruses,
but flash-freezing is not ideal for standard histological prep-
aration because of ice crystal artifacts and cell culture.
Light Microscopic Examination and Stains
For routine light microscopy examination, EMB tissue is
embedded in paraffin, and serial sections are obtained and
sequentially numbered (23). For suspected myocarditis, many
laboratories will stain every third piece for hematoxylin and
eosin and the middle 2 pieces for Movat or elastic trichrome
stain to visualize collagen and elastic tissue. Many laborato-
ries also routinely stain 1 slide for iron on men and all
postmenopausal women, regardless of the indication for EMB
(23). Congo red staining may be performed on 10- to 15-m
sections to rule out amyloidosis. The remaining slides are
usually preserved for immunohistochemistry.
Molecular Biological Detection of Viral
Genomes
Recent advances in quantitative (qPCR) and qualitative
(nested PCR) molecular techniques can detect fewer than 10
gene copies of viral pathogens in the myocardium. These
highly sensitive techniques provide both challenges and
opportunities. The clinical impact on prognosis and treatment
Table 1. Risks Associated With Endomyocardial Biopsy in
546 Procedures
Overall 33 complications (6%)
Sheath insertion 15 (2.7%)
12 (2.0%) arterial puncture during local anesthesia
2 (0.4%) vasovagal reaction
1 (0.2%) prolonged venous oozing after sheath removal
Biopsy procedure 18 (3.3%)
6 (1.1%) arrhythmia
5 (1.0%) conduction abnormalities
4 (0.7%) possible perforation (pain)
3 (0.5%) definite perforation (pericardial fluid)
2 of 3 patients with definite perforation died
Data derived from Deckers et al (20).
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largely depends on establishing a standardized set of diag-
nostic methods. PCR analysis for viral genomes can yield
false results if the sample is not rapidly and properly
transported from the catheterization laboratory to the
laboratory bench. To prevent sample degradation and
contamination, the use of pathogen-free biopsy devices
and storage vials is required. New fixatives such as
RNAlater (Ambion, Austin, Tex) allow PCR and rtPCR to
be performed on samples transported on dry ice at room
temperature without loss of sensitivity compared with
frozen tissue that is transported on ice.
Over the past 2 decades, the use of nested PCR has
substantially increased the information about possible cardio-
tropic viruses in patients with acquired heart disease. Multiple
studies of patients with myocarditis or dilated cardiomyopa-
thy (DCM) reported a wide range of viruses, including
enteroviruses, adenoviruses, parvovirus B19, cytomegalovi-
rus, influenza and respiratory syncytial virus, herpes simplex
virus, Epstein-Barr virus, human herpesvirus 6, HIV, and
hepatitis C (27–36). In a comprehensive study by Bowles et
al (31), nested PCR amplified a viral product in 40% of 773
samples primarily from patients 18 years of age with
myocarditis (n624) or DCM (n149). In this study, ade-
novirus and enterovirus genomes were the most frequent (31).
In adults with DCM or unexplained global or regional left
ventricular dysfunction, enterovirus, parvovirus B19, human
herpes virus 6, or multiple genomes were frequently detected
in EMB of consecutively analyzed patients (34).
Specialized virological laboratories also use real-time
PCR, a more quantitative approach, to estimate viral loads in
the majority of cardiotropic viruses. Virus loads have been
reported to be between 50 and 500 000 copies/g in parvo-
virus B19 –positive patients (37). Unfortunately, the clinical
application of real-time PCR is also hampered by sampling
error in focal disease and the frequent late timing of EMB
after disease onset. Indeed, no published data exist on
real-time PCR sampling error or associations of viral loads
with clinical outcomes.
Therefore, a limitation for the interpretation of viral ge-
nome data remains uncertain sensitivity. Because the number
of pieces needed to attain a clinically acceptable sensitivity
for cardiotropic viruses is not known, only a positive PCR
result is diagnostic, whereas a negative PCR does not exclude
viral disease. Because of uncertainties in the methods and
interpretation at centers not experienced in these techniques,
the Writing Group consensus is that routine testing for viral
genomes in EMB specimens is not recommended at this time
outside of centers with extensive experience in viral genome
analysis.
When Should EMB Be Performed?
Most publications on the use of EMB are only accessible
through multiple literature searches by specific pathological
diseases, such as lymphocytic myocarditis or giant cell
myocarditis (GCM). The Writing Group recognized that a
major obstacle to the clinical use of these data is that
decisions to proceed with EMB are made on the basis of
clinical presentations, not of pathological diagnoses, which
are known only after the procedure. To create a set of
clinically useful recommendations, the writing group mem-
bers extracted and synthesized the presenting scenarios from
pathology-focused publications in which EMB was used to
obtain tissue. The novel result of this effort is a set of distinct
clinical scenarios from which a practical decision to proceed
with EMB can be made.
One broad conclusion of the committee members is that
EMB is not commonly indicated in the evaluation of heart
disease. In this regard, the results presented in this Scientific
Statement are in agreement with the recommendations for
EMB from the current AHA/ACC guideline on the Diagnosis
and Management of Chronic Heart Failure in the Adult (38),
the Heart Failure Society of America Heart Failure Practice
Guideline (39), and the ESC Heart Failure guidelines (40).
However, there are specific clinical circumstances in which
EMB results may meaningfully estimate prognosis or guide
treatment. The present Scientific Statement also explores the
indications for EMB besides unexplained cardiomyopathy.
Because no randomized, controlled treatment data exist on
the utility of biopsy, the recommendations of this writing
group are based on case–control series and expert opinion,
which are summarized in Table 2.
The definitions of key terms relevant to the clinical
scenarios that follow are provided to clarify the interpretation
of the committee’s recommendations. Unexplained heart
failure refers to a clinical setting where appropriate tests to
exclude common forms of cardiomyopathy have been per-
formed and fail to reveal the diagnosis. These tests usually
include an ECG, chest radiograph, and echocardiography to
identify valvular, congenital, or pericardial causes for heart
failure and coronary angiography for the evaluation of coro-
nary artery disease. Other tests may include CT or magnetic
resonance imaging, depending on the clinical setting.
Throughout this document, “ventricular arrhythmia” refers to
ventricular fibrillation or sustained and nonsustained ventric-
ular tachycardia usually associated with hemodynamic
compromise.
Clinical Scenario 1
EMB should be performed in the setting of unexplained,
new-onset heart failure of <2 weeks’ duration associated
with a normal-sized or dilated left ventricle in addition to
hemodynamic compromise. Class of Recommendation I,
Level of Evidence B.
Adult and pediatric patients who present with the sudden
onset of severe left ventricular failure within 2 weeks of a
distinct viral illness and who have typical lymphocytic
myocarditis on EMB have an excellent prognosis (41,42).
These patients often are in cardiogenic shock and require
intravenous inotropic agents or mechanical assistance for
circulatory support. The left ventricle is often thick but not
dilated, and the ejection fraction (EF) is markedly depressed
(43). Patients of this type who have lymphocytic myocarditis
on EMB are uncommon and poorly represented in the
randomized trials of acute myocarditis and cardiomyopathy
(44,45). Therefore, there are too few data on immunosuppres-
sive treatment of fulminant myocarditis in the adult popula-
tion to assess the efficacy or safety of intravenous immuno-
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globulin or corticosteroids in this disorder. However, if other
causes of heart failure (such as coronary artery disease) are
excluded, EMB can provide unique prognostic information
and exclude clinically more aggressive disorders.
GCM and necrotizing eosinophilic myocarditis may pres-
ent with a fulminant clinical course, but unlike fulminant
lymphocytic myocarditis, both disorders have a poor progno-
sis (46). Necrotizing eosinophilic myocarditis is a rare con-
dition known only from small case series and case reports.
The prognosis is poor, with most cases diagnosed at autopsy
(47). This form of eosinophilic heart disease is characterized
by an acute onset and rapid progression of hemodynamic
compromise. Histologically, necrotizing eosinophilic myo-
carditis may be identified by a diffuse inflammatory infiltrate
with predominant eosinophils associated with extensive myo-
cyte necrosis (48). Necrotizing eosinophilic myocarditis dif-
fers from typical hypersensitivity myocarditis (HSM) in that
the lesions are diffuse rather than perivascular and interstitial,
and myocyte necrosis is prominent. A histological diagnosis
on EMB alters prognosis and would lead to immunosuppres-
sive treatment.
Therapy with combinations of immunosuppressive agents
has been associated with improved outcome in GCM and
necrotizing eosinophilic myocarditis (46,49). The sensitivity
of EMB for lymphocytic myocarditis is variable and depends
on the duration of illness. In subjects with symptom duration
of 4 weeks, up to 89% may have lymphocytic myocarditis
(50), but generally the yield is lower, between 10% and 35%
depending on the “gold standard” used (1,51). In contrast, the
sensitivity of EMB for GCM is 80% to 85% in subjects who
subsequently die or undergo heart transplantation (52). In the
setting of anticipated mechanical circulatory device support, a
pathological diagnosis of GCM may lead to use of a biven-
tricular device because of the likelihood of progressive right
ventricular failure. Thus, EMB may provide unique and
clinically meaningful information and should be performed in
the setting of unexplained, new-onset heart failure of 2
weeks’ duration associated with a normal-sized or dilated left
ventricle in addition to hemodynamic compromise.
Clinical Scenario 2
EMB should be performed in the setting of unexplained
new-onset heart failure of 2 weeks’ to 3 months’ duration
associated with a dilated left ventricle and new ventricu-
lar arrhythmias, Mobitz type II second- or third-degree
atrioventricular (AV) heart block, or failure to respond to
usual care within 1 to 2 weeks. Class of Recommendation
I, Level of Evidence B.
Although most cases of acute DCM are relatively mild and
resolve with few short-term sequelae, certain signs and
symptoms predict GCM, a disorder with a mean
transplantation-free survival duration of only 5.5 months
(46). GCM is associated with a variety of autoimmune
disorders, thymoma (53), and drug hypersensitivity (54). At
presentation, ventricular tachycardia is present in 15% of
cases, complete heart block in 5%, and an acute coronary
syndrome in 6%—rates higher than are typically seen in
noninflammatory DCM. In follow-up, 29% of GCM patients
developed ventricular tachycardia and 15% developed AV
block (8% complete) (55). Thus, clinical clues to suggest









1 New-onset heart failure of 2 weeks’ duration associated with a normal-sized or dilated left ventricle and
hemodynamic compromise
I B
2 New-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle and new
ventricular arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to
2 weeks
I B
3 Heart failure of 3 months’ duration associated with a dilated left ventricle and new ventricular
arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to 2 weeks
IIa C
4 Heart failure associated with a DCM of any duration associated with suspected allergic reaction and/or
eosinophilia
IIa C
5 Heart failure associated with suspected anthracycline cardiomyopathy IIa C
6 Heart failure associated with unexplained restrictive cardiomyopathy IIa C
7 Suspected cardiac tumors IIa C
8 Unexplained cardiomyopathy in children IIa C
9 New-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle, without
new ventricular arrhythmias or second- or third-degree heart block, that responds to usual care within 1 to
2 weeks
IIb B
10 Heart failure of 3 months’ duration associated with a dilated left ventricle, without new ventricular
arrhythmias or second- or third-degree heart block, that responds to usual care within 1 to 2 weeks
IIb C
11 Heart failure associated with unexplained HCM IIb C
12 Suspected ARVD/C IIb C
13 Unexplained ventricular arrhythmias IIb C
14 Unexplained atrial fibrillation III C
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GCM and prompt an EMB include association with other
autoimmune disorders or thymoma, failure to respond to
usual care, and the presence of complete heart block or
ventricular tachycardia.
Patients with acute heart failure due to GCM respond well
to heart transplantation. Alternatively, treatment with combi-
nation immunosuppression may improve transplantation-free
survival duration compared with patients with GCM not
receiving immunosuppressive treatment. Patients treated
without immunosuppressive therapy had a median
transplantation-free survival duration of 3.0 months, com-
pared with a 12.3-month (P0.003) median transplantation-
free survival duration for patients treated with cyclosporine-
based immunosuppression. Therefore, a diagnosis of GCM
will affect prognosis and treatment. A comparison of survival
between patients in the multicenter Giant Cell Myocarditis
Registry and those from the Myocarditis Treatment Trial
(lymphocytic myocarditis) showed that patients with GCM
had a significantly poorer prognosis. At 4 years, only 11% of
patients with GCM were alive without transplantation, com-
pared with 44% of patients with lymphocytic myocarditis.
On the basis of these reports, the Writing Group recom-
mends that EMB be performed in the setting of unexplained,
new-onset heart failure of 2 weeks’ to 3 months’ duration
associated with a dilated left ventricle and new ventricular
arrhythmias, Mobitz type II second- or third-degree AV heart
block, or failure to respond to usual care within 1 to 2 weeks.
Clinical Scenario 3
EMB is reasonable in the clinical setting of unexplained
heart failure of >3 months’ duration associated with a
dilated left ventricle and new ventricular arrhythmias,
Mobitz type II second- or third-degree AV heart block, or
failure to respond to usual care within 1 to 2 weeks. Class
of Recommendation IIa, Level of Evidence C.
Patients who present with heart failure of 3 months’
duration associated with a dilated left ventricle and new
ventricular arrhythmias, second- or third-degree heart block,
or failure to respond to usual care within 1 to 2 weeks are at
risk for cardiac sarcoidosis or idiopathic granulomatous
myocarditis. Cardiac sarcoidosis is present in 25% of
patients with systemic sarcoidosis (56), but symptoms refer-
able to cardiac sarcoidosis occur in only 5% of sarcoid
patients (55,57), and up to 50% of patients with granuloma-
tous inflammation in the heart have no evidence of extracar-
diac disease. Patients with cardiac sarcoidosis sometimes may
be distinguished from those with DCM by a high rate of heart
block (8% to 67%) and ventricular arrhythmias (29%) (58 –
61). The rates of ventricular tachycardia and heart block are
therefore similar in cardiac sarcoidosis and GCM, but cardiac
sarcoidosis generally has a more chronic course.
Histologically, sarcoidosis consists of noncaseating granu-
lomas with fibrosis, few eosinophils, and little myocyte
necrosis (62). In a study of 26 patients in whom cardiac
sarcoidosis was strongly suspected on the basis of clinical
diagnostic criteria for sarcoidosis, ECG abnormalities, or
noninvasive imaging (63), noncaseating granulomata were
found in only 19.2% of the patients, which confirmed earlier
reports that the sensitivity of EMB for sarcoidosis is20% to
30% (64). Thus, the heterogeneous myocardial distribution of
sarcoid heart disease may lead to sampling error and decrease
the diagnostic rate of the EMB. In patients with biopsy-
proven pulmonary sarcoid, CMR has been used to infer
cardiac involvement and localize disease activity (65).
Even though the diagnostic rate of the EMB in cardiac
sarcoidosis is low, a histological distinction between cardiac
sarcoidosis and GCM (both of which have giant cells) is
important for therapeutic decisions and prognosis. The rate of
transplantation-free survival at 1 year is significantly worse in
patients diagnosed by EMB with idiopathic GCM than in
patients with cardiac sarcoidosis (21.9% versus 69.8%;
P0.0001) (61). Reports differ as to whether survival rate in
cardiac sarcoidosis is similar to or worse than in DCM (1,58,66).
Sarcoidosis may respond to treatment with corticosteroids.
Rate of survival was better in those who received corticosteroids
than in those who received usual care (64% versus 40%;
P0.048) in one retrospective study (67). Small case series and
case reports also suggest that corticosteroids may improve
clinical status and ventricular function, particularly if used early
in the course of disease, but their benefit on ventricular arrhyth-
mias is less certain (64,68,69). Implantable cardiac defibrillators
may be effective in treating arrhythmias in patients with ven-
tricular tachycardia related to sarcoidosis (70,71). After exten-
sive fibrosis of the left ventricle, steroid use is probably of little
benefit. Therefore, EMB is reasonable in the clinical setting of
unexplained heart failure of 3 months’ duration associated
with a dilated left ventricle and new ventricular arrhythmias,
Mobitz type II second- or third-degree AV heart block, or failure
to respond to usual care within 1 to 2 weeks.
Clinical Scenario 4
EMB is reasonable in the setting of unexplained heart failure
associated with a DCM of any duration that is associated
with suspected allergic reaction in addition to eosinophilia.
Class of Recommendation IIa, Level of Evidence C.
HSM is an uncommon disorder with a wide range of
presentations, including sudden death, rapidly progressive
heart failure, or more chronic DCM. Clinical clues that are
reported in a minority of cases include rash, fever, and
peripheral eosinophilia. A temporal relation with recently
initiated medications or the use of multiple medications is
usually present (72). The ECG is often abnormal, with
nonspecific ST-segment changes or infarct patterns similar to
other forms of acute myocarditis. The prevalence of clinically
undetected HSM in explanted hearts ranges from 2.4% to 7%
(73) and has been associated with dobutamine (74).
Early suspicion and recognition of HSM may lead to with-
drawal of offending medications and administration of high-dose
corticosteroids. The hallmark histological findings of HSM
include an interstitial infiltrate with prominent eosinophils with
little myocyte necrosis; however, GCM, granulomatous myocar-
ditis, or necrotizing eosinophilic myocarditis may also be a
manifestation of drug hypersensitivity (54) and may be distin-
guished from common forms of HSM only by EMB.
Eosinophilic myocarditis associated with the hypereosino-
philic syndrome is a form of eosinophilic myocarditis that
typically evolves over weeks to months. The presentation is
usually biventricular heart failure, although arrhythmias may
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lead to sudden death. Usually hypereosinophilia precedes or
coincides with the onset of cardiac symptoms, but the eosino-
philia may be delayed (75). Eosinophilic myocarditis may also
occur in the setting of malignancy or parasite infection and early
in the course of endocardial fibrosis. Because EMB may
distinguish HSM from GCM or necrotizing eosinophilic myo-
carditis, EMB is reasonable in the setting of unexplained heart
failure associated with a DCM of any duration associated with
suspected allergic reaction in addition to eosinophilia.
Clinical Scenario 5
EMB is reasonable in the setting of unexplained heart failure
associated with suspected anthracycline cardiomyopathy.
Class of Recommendation IIa, Level of Evidence C.
Certain chemotherapeutic agents, particularly anthracy-
clines, are known to be cardiotoxic, particularly at higher
cumulative doses. Although cardiotoxicity may be monitored
by several modalities, including echocardiographic or radio-
nuclide angiography assessment of EF, fractional shortening,
or parameters of diastolic dysfunction, these modalities are
generally regarded as capable of detecting more advanced
stages of cardiotoxicity rather than earlier degrees of cardio-
toxicity. Nevertheless, these techniques are noninvasive and
thus widely used in routine clinical practice. EMB, though an
invasive procedure, is considered to be the most sensitive and
specific means of evaluating cardiotoxicity.
Examination of biopsy specimens in anthracycline-induced
cardiomyopathy with electron microscopy demonstrates charac-
teristic changes, including extensive depletion of myofibrillary
bundles, myofibrillar lysis, distortion and disruption of the
Z-lines, mitochondrial disruption, and intramyocyte vacuoliza-
tion (76). A grading system is used to score toxicity on the basis
of the percentage of biopsy specimen cells that demonstrate
associated toxicity, with a score of 1 indicating 5% biopsy
specimen cell involvement and 3 representing 35% involve-
ment (76,77).
Early study of the procedure demonstrated that in patients
with risk factors, the use of EMB, along with hemodynamic
data, reduced the rate of doxorubin-induced heart failure
when compared with monitoring without invasive studies
(78). A good correlation was found between cumulative
adriamycin dose and EMB grade (although the correlation
between changes in biopsy grade and EF was poor) (79). In
one series, patients with a biopsy grade 1.5 had a 20%
chance of cardiac failure with continued therapy (80). With
its ability to detect earlier stages of cardiac toxicity, as well as
its sensitivity and specificity, EMB has been used in studies
of newer chemotherapeutic agents and regimens (81– 84).
The threshold to perform biopsy may also be influenced by
the prior use of concomitant therapies known to potentiate
anthracycline-induced cardiotoxicity, including radiation,
herceptin, and cyclophosphamide.
Given its invasive nature, EMB in patients treated with
chemotherapeutic agents may be best suited for situations in
which there is question as to the cause of cardiac dysfunction
(76), as well as in select cases in which ultimate administration
of greater than the usual upper limit of an agent is believed to be
desirable, and in clinical studies of chemotherapeutic-related
toxicity of newer agents and regimens (85,86).
Clinical Scenario 6
EMB is reasonable in the setting of heart failure associ-
ated with unexplained restrictive cardiomyopathy. Class
of Recommendation IIa, Level of Evidence C.
Of the 3 major functional categories of the cardiomyopa-
thies (dilated, hypertrophic, and restrictive), restrictive car-
diomyopathy is the least common form in adults and in
children. Typically, a patient presents with symptoms of heart
failure and on echocardiogram is found to have normal or
decreased volume of both ventricles, biatrial enlargement,
normal or minimally increased wall thickness with no valvu-
lar abnormality, or normal or near-normal systolic function
with impaired diastolic filling, for example, restrictive phys-
iology. As shown in Table 3, this category of cardiomyopathy
has been further classified into noninfiltrative processes,
infiltrative disorders, and storage diseases that cause charac-
teristic ventricular filling abnormalities, as well as the endo-
myocardial diseases that have many of the same clinical
manifestations (87). Thus, a variety of pathological processes
may result in restrictive cardiomyopathy, although the cause
often remains unknown. More importantly, the clinical and


























Toxic effects of anthracycline*
Drugs causing fibrous endocarditis (serotonin, methysergide, ergotamine,
mercurial agents, busulfan)
*This condition is more likely than the others to be encountered in clinical
practice.
Adapted from Kushwaha et al (87) with permission from the Massachusetts
Medical Society. Copyright 1997, The Massachusetts Medical Society.
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hemodynamic features of many types of restrictive cardio-
myopathy may mimic those of constrictive pericarditis
(88,89). EMB, in combination with either CT or CMR, can
be helpful in differentiating the 2 clinical entities restric-
tive cardiomyopathy and constrictive pericarditis. EMB
may reveal either a specific infiltrative disorder, for
example, amyloidosis or hemochromatosis, or myocardial
fibrosis and myocyte hypertrophy consistent with idio-
pathic restrictive cardiomyopathy. However, if pericardial
thickening is noted on CT or CMR and the physiology is
most consistent with constrictive pericarditis, EMB is
often not needed. Because of the frequency of treatable
disorders, EMB is reasonable in the setting of heart failure
associated with unexplained restrictive cardiomyopathy.
Clinical Scenario 7
EMB is reasonable in the setting of suspected cardiac
tumors, with the exception of typical myxomas. Class of
Recommendation IIa, Level of Evidence C.
There are several dozen case reports and one small series of
EMB being used for the tissue diagnosis of cardiac tumors
(14,90 –106). Over the past decade, such biopsy usually has
been performed with the aid of transesophageal echocardiog-
raphy. Lesions have been biopsied in all 4 cardiac chambers,
though most reports are of right-sided tumors. Biopsy has
resulted in diagnoses such as primary cardiac lymphoma,
non-Hodgkin’s lymphoma, cardiac sarcoma, cervical carci-
noma, melanoma, hepatocellular carcinoma, and pulmonary
microcytoma; lymphoma is the most commonly reported
tumor. Most tumors were suspected, although several have
been serendipitously discovered during biopsy for other
indications. The actual yield of EMB for suspected cardiac
tumor cannot be defined because the number of nondiagnos-
tic and unpublished procedures could never be determined.
Similarly, the complication rate of such procedures cannot be
definitively determined, although none of the published
reports of EMB for suspected tumor note any major compli-
cations. Because right heart myxomas can embolize to the
lungs with manipulation, EMB is not usually warranted if the
appearance is typical on noninvasive imaging.
Therefore, EMB for suspected cardiac tumor seems a
reasonable procedure if (1) the diagnosis cannot be estab-
lished by noninvasive modalities (such as cardiac CMR) or
less invasive (noncardiac) biopsy; (2) tissue diagnosis can be
expected to influence the course of therapy; (3) the chances of
successful biopsy are believed to be reasonably high; and (4)
the procedure is performed by an experienced operator.
Guidance with transesophageal echocardiography or CMR is
advised when possible.
Clinical Scenario 8
EMB is reasonable in the setting of unexplained cardio-
myopathy in children. Class of Recommendation IIa, Level
of Evidence C.
As in adults, the major indications for EMB in children
include fulminant or acute unexplained heart failure, cardiac
transplant surveillance or rejection evaluation, unexplained
arrhythmias, and idiopathic forms of DCM. Rarely, patients
with other forms of cardiomyopathy, including arrhythmo-
genic right ventricular dysplasia/cardiomyopathy (ARVD/C),
restrictive cardiomyopathy, and hypertrophic cardiomyopa-
thy (HCM), undergo EMB. In nearly all instances, the
biopsies are performed in the right ventricle under sedation or
anesthesia (107). The reported experience with EMB in
children consists of case reports and case series, and therefore
the recommendations of this Writing Group are based on
expert opinion.
Most cases of myocarditis in children are viral induced,
have acute onset, and present with heart failure, cardiovas-
cular collapse, or unexplained arrhythmias (usually ventricu-
lar tachycardia) (107,108) or conduction disease (typically
AV block). The histopathologic picture is similar to that seen
in adults, although it appears to be virus specific. For
instance, enteroviruses such as coxsackievirus are consis-
tently associated with classic frank myocarditis by histology,
whereas adenovirus is most commonly associated with his-
tological features of borderline myocarditis. Parvovirus,
Ebstein-Barr virus, and cytomegalovirus appear to have
variable histological features (31,109).
Outcomes of young children (1 year of age) with
myocarditis appear to be worse than those of older children
and also appear to be associated with viral pathogenesis, with
adenovirus having the worst prognosis (31). However, the
underlying viruses have changed over the decades, with
coxsackievirus common in the 1980s through 1990s, fol-
lowed by a predominance of adenovirus in the 1990s, and
now replaced by parvovirus B19. Similar data have been
noted in children after transplantation. Shirali et al (110)
demonstrated that children with PCR evidence of adenovirus
in EMB samples have a 5-year survival rate of 66%, whereas
PCR-negative patients had a 5-year survival rate of 95%. The
present Writing Group’s assessment is that EMB is reason-
able in the setting of unexplained cardiomyopathy in children
(Class of Recommendation IIa, Level of Evidence C).
Clinical Scenario 9
EMB may be considered in the setting of unexplained,
new-onset heart failure of 2 weeks’ to 3 months’ duration
associated with a dilated left ventricle, without new ven-
tricular arrhythmias or Mobitz type II second- or third-
degree AV heart block, that responds to usual care within
1 to 2 weeks. Class of Recommendation IIb, Level of
Evidence B.
The utility of EMB in patients with DCM of 2 weeks’ to 3
months’ duration is less certain than in patients with 2
weeks of symptoms because most patients with uncompli-
cated acute idiopathic dilated cardiomyopathy improve with
standard heart failure care. Furthermore, several studies have
demonstrated a wide variation in the incidence in which the
pathological diagnosis of lymphocytic myocarditis is made,
ranging from 0% to 63% (111). This can be attributed to
variation in the patient populations studied, sampling error,
and variability in pathological interpretation. In cases in
which EMB is positive, lymphocytic myocarditis is the most
frequent form of myocarditis seen. Studies with a high
incidence rate of lymphocytic myocarditis found on biopsy
usually involved patients with acute heart failure with symp-
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tom onset within 1 month (50), rather than patients who had
had symptoms for months to years.
Lack of a consensus definition for diagnosing lymphocytic
myocarditis on EMB also contributed to the variation. Formal
criteria, called the Dallas criteria, were established in 1986
(112) and were used in the National Heart, Lung, and Blood
Institute–sponsored Myocarditis Treatment Trial (44). The
Dallas criteria have been questioned as the gold standard for
diagnosis of myocarditis because of sampling error, interob-
server variability in histopathologic interpretation, and lack of
correlation between Dallas criteria myocarditis and demon-
stration of viral genomes in heart tissue (113).
Prognosis varies with results of EMB because the risk of
death or heart transplantation in lymphocytic myocarditis
with 2 weeks or more of symptoms and lack of a distinct viral
prodrome is greater than in fulminant lymphocytic myocar-
ditis described in clinical scenario 1; however, the presence of
lymphocytic myocarditis on EMB in this clinical setting
rarely affects treatment. For example, in the Myocarditis
Treatment Trial, 111 patients with active or borderline
myocarditis on EMB and left ventricular EF of 45% were
randomized to conventional therapy or a 24-week immuno-
suppressive regimen consisting of either prednisone and
azathioprine or prednisone and cyclosporine (44). The aver-
age symptom duration before treatment was 4 weeks, and the
primary end point was the change in EF after 28 weeks. The
average EF and the median transplantation-free survival
duration were similar in the immunosuppression and conven-
tional therapy groups. The risk of death or transplantation was
56% at 4 years. Similarly, in the Immunoglobulin for Myo-
carditis and Acute Cardiomyopathy (IMAC-1) trial of intra-
venous immunoglobulin for acute nonischemic DCM, at 2
years the risk of death or transplantation was 12%. Sixteen
percent of patients in the IMAC-1 study had borderline or
active myocarditis (45). Grogan et al (114) compared the
prognosis of patients with acute DCM with and without
myocarditis and found that the survival rate in patients with
Dallas criteria myocarditis was the same as in those with no
inflammation. From these 3 studies, subjects with acute DCM
who also have myocarditis as defined by the Dallas criteria do
not seem to respond to immunosuppressive therapies, includ-
ing intravenous immunoglobulin. Therefore, the information
gained from the Dallas criteria does not alter prognosis or
therapy in most patients. On the basis of these reports, the
Writing Group does not recommend performing EMB for the
routine evaluation of new-onset heart failure of 2 weeks’ to 3
months’ duration associated with a dilated left ventricle,
without new ventricular arrhythmias or second- or third-
degree heart block, that responds to usual care within 1 to 2
weeks. Immunoperoxidase stains, including novel immune
markers such as human leukocyte antigen (HLA)-ABC and
HLA-DR, may affect prognosis and guide therapy in the
future, but these are not in routine clinical use at the present
time (113,115–117).
Clinical Scenario 10
EMB may be considered in the setting of unexplained
heart failure of >3 months’ duration associated with a
dilated left ventricle, without new ventricular arrhythmias
or Mobitz type II second- or third-degree AV heart block,
that responds to usual care within 1 to 2 weeks. Class of
Recommendation IIb, Level of Evidence C.
The role of EMB in chronic, symptomatic DCM has been
the focus of recent research articles, particularly in viral-
associated cardiomyopathy. Some patients who have symp-
tomatic heart failure and DCM after 6 months of optimal
therapy may benefit from immunomodulation or antiviral
therapy. Two recent trials examined patients with DCM,
symptom duration of 6 months, and cardiomyocyte HLA-
ABC and HLA-DR antigen expression on EMB. Treatment
with atorvastatin (117) or azathioprine and prednisone (115)
resulted in improved EF. In both trials, the test used to
classify these patients as having persistent immune activation
was an immunoperoxidase stain for HLA-ABC or HLA-DR,
a more sensitive marker of cardiac inflammation than lym-
phocyte infiltration (118). If these data are confirmed in a
larger trial with clinically meaningful end points, EMB may
have a greater role in the evaluation of chronic DCM (119).
Another group of patients who may present with chronic
DCM are individuals with hereditary or acquired hemochro-
matosis. Cardiac involvement in hemochromatosis usually
can be diagnosed on the basis of history, clinical examination,
and echocardiography or CMR demonstrating DCM in the
setting of laboratory abnormalities such as elevated serum
iron and HFE gene mutation. In the event that findings are
equivocal and the possibility of cardiac hemochromatosis still
exists, EMB can be useful for diagnosis and to guide
treatment. Iron deposition is seen within the sarcoplasm
(120). Treatment with phlebotomy or iron chelation therapy
can reverse the ventricular dysfunction (121).
On the basis of these reports, the Writing Group recognizes
that divergent evidence exists with regard to the utility of
EMB in this clinical scenario. The Writing Group recom-
mends that EMB may be considered in the setting of
unexplained heart failure of 3 months’ duration associated
with a dilated left ventricle, without new ventricular arrhyth-
mias, or Mobitz type II second- or third-degree AV heart
block, that responds to usual care within 1 to 2 weeks (Class
of Recommendation IIb, Level of Evidence C).
Clinical Scenario 11
EMB may be considered in the setting of heart failure
associated with unexplained HCM. Class of Recommen-
dation IIb, Level of Evidence C.
HCM occurs in an autosomal dominant pattern in 1:500 of
the general population recognized to have the clinical pheno-
type (122), which makes it the most frequently occurring
cardiomyopathy. HCM may present as sudden cardiac death
in the young and may also cause heart failure at any age.
HCM is defined by a hypertrophied, nondilated left ventricle
in the absence of other systemic or cardiac disease that might
result in left ventricular wall thickening to the magnitude that
is seen in HCM, eg, systemic hypertension or aortic stenosis.
The diagnosis is made by echocardiography or magnetic
resonance imaging, which shows left ventricular wall thick-
ening, small left ventricular cavity, and sometimes a dynamic
outflow obstruction. EMB is not usually needed in the
evaluation of HCM but may be considered in those cases in
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which unexplained wall thickening prompts an effort to
exclude infiltrative disorders such as Pompe’s or Fabry’s
diseases and noninvasive tests are inconclusive. Occasional
patients being considered for surgical myomectomy may
benefit from EMB before surgery to exclude Fabry’s disease,
which may respond to enzyme replacement therapy (123).
Senile, transthyretin-associated, and primary (AL) amy-
loidosis may have cardiac involvement that results in a
dilated, restrictive, or hypertrophic pattern of cardiomyopathy
(124). When cardiac amyloidosis is present, low voltage on
ECG and left ventricular hypertrophy on echocardiogram
strongly support the diagnosis (125). Prognosis in cardiac
amyloidosis is much worse if either histological evidence of
myocarditis or elevated serum troponin are present (125,126).
Immunohistochemistry performed on heart tissue can distin-
guish among types of amyloidosis, which have specific
therapies. Often the diagnosis can be established from less
invasive procedures, such as fat pad or bone marrow biopsies;
however, in patients in whom clinical evaluation is equivocal,
EMB can be used to establish the diagnosis and guide
treatment (127).
Clinical Scenario 12
EMB may be considered in the setting of suspected
ARVD/C. Class of Recommendation IIb, Level of Evidence C.
ARVD/C, an inherited or sporadic form of right and left
ventricular cardiomyopathy, is estimated to occur in 1:5000
persons. The disorder involves predominantly the right ven-
tricle, with progressive loss of myocytes that are replaced by
fibrofatty tissue, resulting in ventricular dysfunction and
tachyarrhythmias, typically monomorphic ventricular
tachycardia (128 –130). Noninvasive tests, including echocar-
diography, right ventricular angiography, cardiac CMR, and
cardiac CT imaging, often establishes the diagnosis. In a
study of the use of CMR in 40 patients with AVRD/C and 20
normal subjects, the sensitivity of fat infiltration, right ven-
tricular enlargement, and regional right ventricular dysfunc-
tion for diagnosing ARVD/C was 84%, 68%, and 78%, and
specificity was 79%, 96%, and 94%, respectively (131).
The use of EMB for ARVD/C has been controversial
because of the perceived risk of perforation of the thin-walled
right ventricle with fibrofatty replacement, but the few reports
of EMB for AVRD/C do not report a high rate of complica-
tions (132,133). Within the pediatric population, this disease
occurs nearly exclusively in adolescents and young adults,
who have a lower risk than infants. Nonetheless, experts in
this field disagree as to the risks of the procedure. The
histopathologic findings from EMB may be diagnostic of
ARVD/C if performed in the appropriate position in the right
ventricle (134). Diagnosis relies on the finding of fibrofatty
replacement of sufficient degree. Bowles and colleagues
(135) also demonstrated that some cases are associated with
viral genome in the myocardium. A high percentage of biopsy
and autopsy studies in patients with ARVD/C have associated
inflammatory infiltrates, but the prognostic relevance of these
lesions is uncertain. Recognizing that there is a wide spec-
trum of clinical practice in the use of EMB in the manage-
ment of suspected AVRD/C and scarce data to inform this
practice, the Writing Group recommends that EMB may be
considered in the setting of suspected ARVD/C (Class IIb,
Level of Evidence C).
Clinical Scenario 13
EMB may be considered in the setting of unexplained
ventricular arrhythmias. Class of Recommendation IIb,
Level of Evidence C.
There is modest published literature on the use of EMB in
patients with primary or idiopathic (eg, without known
structural heart disease or predisposing disease) arrhythmias
and primary conduction abnormalities. Many of these studies
were conducted in the 1980s, and most involve only modest
numbers of patients (Table 4).
Most studies reported a high incidence of abnormal find-
ings, although these were usually nonspecific findings; the
incidence of histologically diagnosed myocarditis varied
widely in these reports, and only rarely were other specific
disease entities diagnosed. One authoritative review ques-
tioned the “strikingly high” incidence of reported histological
myocardial abnormalities in the literature, and the review
authors comment that they suspect the true incidence of
abnormalities described in these reports to be lower (136).
Notably, biopsy is not believed to be able to detect abnor-
malities that are present in only the conduction system (137).
Hosenpud et al (138) reported that in 10 patients with
life-threatening arrhythmias in the absence of structural heart
disease, EMB demonstrated lymphocytic myocarditis in 2
patients, granulomatous myocarditis in 2 patients, and small-
vessel vasculitis in 1 patient. In another series of 14 patients
with high-grade ventricular arrhythmias and no structural
heart disease, EMB was normal in 6 patients and demon-
strated nonspecific abnormalities, predominantly fibrosis, in
the other patients. In this series, abnormal biopsy findings did
not correlate with induced arrhythmias or prognosis. No
specific treatable diagnoses were revealed by biopsy in this
series (139). In a third case series, EMB in 12 patients with
serious ventricular arrhythmias and structurally normal hearts
demonstrated nonspecific abnormalities in 11 patients and
acute lymphocytic myocarditis in 1 patient (140). Vignola et
al (141) reported that in 12 patients with high-grade ventric-
ular arrhythmias and without overt cardiac disease, EMB led
to a diagnosis of clinically unsuspected lymphocytic myocar-
ditis in 6 patients. After 6 months of immunosuppressive
therapy, ventricular arrhythmia could not be provoked in 5 of
the 6 patients (141). Frustaci and colleagues (142) reported on
the results of noninvasive and invasive evaluation, including
right and left heart biopsy, of 17 young patients without overt
organic heart disease who were resuscitated from sudden
cardiac arrest, 9 of whom were subsequently classified as
having structurally normal hearts. Six of these 9 patients
appear to have been classified with histological evidence of
myocarditis. Interestingly, left ventricular biopsy allowed the
diagnoses of myocarditis in 3 patients in whom the diagnosis
would not have been made by right ventricular biopsy (142).
EMB results in 11 children with paroxysmal or incessant
supraventricular tachycardia, the majority of whom had
grossly structurally normal hearts, yielded a high incidence of
nonspecific histopathologic abnormalities, including hyper-
trophy and interstitial fibrosis or disarray. Additionally, it was
1923JACC Vol. 50, No. 19, 2007 Cooper et al.
November 6, 2007:1914–31 Endomyocardial Biopsy in Cardiovascular Disease
speculated that the arrhythmia may have lead to the myocar-
dial damage, rather than vice versa (143). Teragaki and
coworkers (144) examined the results of EMB in 10 patients
with documented AV block without apparent heart disease
who also underwent electrophysiological testing. Seven of the
10 patients were found to have evidence of myocardial
fibrosis, with either myocyte hypertrophy or disarray. The
results of electrophysiological testing did not correlate with
the histopathologic findings or severity (144). In another
report, 19 of 32 patients with various forms of supraventric-




Publication Abnormality Patients, n Findings
Strain et al (157) 1983 Ventricular tachycardia or
ventricular fibrillation
18 16 of 18 patients (89%) with abnormal findings
Nonspecific myocellular hypertrophy, interstitial and
perivascular fibrosis, and vascular sclerosis in 9 of 18
patients, subacute inflammatory myocarditis in 3 of 18
patients, diffuse abnormalities of the intramyocardial
arteries in 2 of 18 patients, and changes consistent with
ARVD/C in 2 of 18 patients
Vignola et al (141) 1984 Malignant ventricular
arrhythmias
12 “Clinically unsuspected myocarditis” in 6 of 12 cases and
“early cardiomyopathy” in 3 of 12 cases
Sugrue et al (140) 1984 Ventricular arrhythmias 12 11 of 12 patients with histological abnormalities
1 of 12 patients with acute lymphocytic myocarditis
Morgera et al (158) 1985 Ventricular tachycardia 10 1 of 6 patients without echocardiographic evidence of
ARVD/C or right ventricular cardiomyopathy had evidence
of myocarditis
Hosenpud et al (138) 1986 Life-threatening
arrhythmias
12 Various forms of myocarditis in 4 of 12 patients, vasculitis
in 1 of 12 patients, and “cardiomyopathic changes” in 6 of
12 patients
Dunnigan et al (159) 1987 Ventricular tachycardia 11 Various nonspecific abnormalities in all 11 of 11 patients
Kobayashi et al (145) 1988 Various supraventricular
tachycardias
50 Myocarditis changes in 6 of 50 patients, postmyocarditic
changes in 15 of 50 patients, and nonspecific
abnormalities in 9 of 50 patients
Nishikawa et al (160) 1990 Various arrhythmias or
AV block
23 (pediatric) Myocyte hypertrophy, disarrangement of muscle bundles,
and/or interstitial fibrosis with or without myocyte
degeneration in 7 of 11 atrioventricular block cases, 1 of 6
premature ventricular contraction cases, and 0 of 3 sick
sinus syndrome cases
Frustaci et al (147) 1991 Lone atrial fibrillation 14 “Cardiomyopathic” changes in 3 of 14 patients, active
myocarditis in 3 of 14 patients, and “nonspecific necrosis
and/or fibrosis” in 8 of 14 patients
Sekiguchi et al (161) 1992 Ventricular tachycardia or
premature ventricular
contractions
43 “Active myocarditis” in 1 patient and “postmyocarditic”
changes in 9 patients
Oakes et al (139) 1992 Ventricular arrhythmias 14 Fibrosis in 6 of 14 patients and monocytes containing
aminosalicylic acid–positive vacuoles in 1 of 14 patients
No specific treatable diagnosis present in any biopsy
Thongtang et al (162) 1993 Various dysrhythmias 53 Myocarditis diagnosed in 18 of 53 patients
Frustaci et al (142) 1994 Young sudden cardiac
death survivors
17 (9 of whom had
structurally normal
hearts)
Histological diagnosis of myocarditis in 6 of 9 patients with
macroscopically structurally normal hearts
Left ventricular biopsy revealed a diagnosis of myocarditis
in 3 of 7 total study patients with normal right ventricular
histology
Yonesaka et al (143) 1996 Children with
supraventricular
tachycardia
11 (4 of whom had
cardiomyopathy)
Frequent nonspecific hypertrophy, degeneration, disarray,
and endomyocardial changes
Speculated that the supraventricular tachycardia causes
the histological changes rather than vice versa
Teragaki et al (144) 1999 AV block 10 Myocardial fibrosis with hypertrophy and/or disarray in 7 of
10 patients
Uemura et al (146) 2001 Second- or third-degree
AV block
50 Frequent myocyte hypertrophy, lymphocytic infiltration,
myocyte disarrangement, myocytolysis, and nuclear
deformity
Myocarditis diagnosed in 6% of patients
Uemura et al (148) 2004 Sick sinus syndrome 25 Frequent myocyte hypertrophy, myocyte size variation,
myocyte disorganization, myocytolysis, and interstitial large
mononuclear cell proliferation
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ular tachycardia and without other clinical abnormalities were
found to have some form of myocardial changes, including 6
with myocarditic changes (145).
Uemura and colleagues (146) also reported on the results
of EMB in 50 patients with second- or third-degree AV block
in whom the cause of the heart block was not clear. Patients
with known coronary artery disease, DCM, cardiac sarcoid-
osis, or “obvious” acute myocarditis were excluded from the
study. The results in these patients were also compared with
the findings from 12 normal hearts. Biopsy specimens in
those with AV block revealed more myocyte hypertrophy,
greater fibrosis, and higher lymphocyte counts than in biopsy
specimens from normal hearts. In addition, specimens from
the group with AV block had variable degrees of myocyte
disorganization and disarrangement, myocytolysis, and nu-
clear deformity. Myocarditis was diagnosed in 3 of the 50
patients (6%) (146).
Thus, EMB in patients with primary (idiopathic) rhythm
abnormalities can be expected to often yield abnormal but
nondiagnostic findings. Although EMB may detect otherwise
clinically unsuspected myocarditis, the value of this finding
in clinical decision making remains controversial. The detec-
tion of active myocarditis in a patient with malignant ven-
tricular arrhythmia might theoretically lead to a decision to
defer implantation of a defibrillator until the myocarditis has
subsided, but such an approach is more theoretical than
tested. Eighteen years ago, Mason and O’Connell (136)
classified the indication for EMB in unexplained, life-
threatening ventricular tachyarrhythmias as “uncertain,” and
it seems there has been little published literature since to
change this classification. Therefore, the Writing Group
recommends that EMB may be considered in the setting of
unexplained ventricular arrhythmias only in exceptional cases
in which the perceived likelihood of meaningful prognostic
and therapeutic benefit outweighs the procedural risks.
Clinical Scenario 14
EMB should not be performed in the setting of unex-
plained atrial fibrillation. Class of Recommendation III,
Level of Evidence C.
Frustaci and colleagues (147) reported on 14 patients with
lone atrial fibrillation unresponsive to usual antiarrhythmic
therapy who underwent extensive evaluation, including
EMB. Some degree of histological abnormalities was present
in all patients, with 3 patients showing cardiomyopathic
changes, 3 other patients showing active myocarditis (lym-
phocytic in 2 and eosinophilic in 1), and 8 patients showing
nonspecific necrosis and/or fibrosis. The addition of steroid
therapy to the patients diagnosed with myocarditis reportedly
resulted in reversion to sinus rhythm. The other patients
continued to have atrial fibrillation (147).
Uemura and colleagues (148) reported on the results of
right ventricular EMB in 25 patients admitted for diagnostic
evaluation of “sick sinus syndrome” who did not have
underlying cardiac disease such as cardiomyopathy or valvu-
lar disease. These results were compared with biopsies from
12 normal autopsied hearts. Compared with normal hearts,
biopsies from those with sick sinus syndrome demonstrated a
larger mean myocyte transverse diameter, greater myocyte
size variation, similar degrees of fibrosis, and similar lym-
phocyte counts. Histologically abnormal findings such as
myocyte disorganization, interstitial mononuclear cells, and
endocardial lesions were only seen in those biopsy specimens
from patients with sick sinus syndrome. No mention is made
of how these findings might have related to clinical manage-
ment (148). On the basis of these reports, the Writing Group
recommends that EMB not be performed in the setting of
unexplained atrial fibrillation.
EMB as a Research Tool
In addition to its clinical roles, EMB may be used to better
understand the cellular and molecular pathophysiology of
cardiovascular disease. For example, the development of
techniques for quantifying gene expression in small amounts
of EMB tissue using PCR (149) led to the finding that
recapitulation of the “fetal gene program” that accompanied
the development of heart failure could be reversed with
normalization of left ventricular function (150) and that
changes in gene expression could be correlated with bio-
chemical and physiological changes in the failing heart (151).
In addition, serial measures of gene expression are useful in
documenting the relationship between biochemical and phe-
notypic changes in the failing heart in response to either
treatment or disease progression (152).
More recently, silicon chip–based technology or mRNA
expression arrays and protein expression through mass spec-
troscopy have also been used to assess the biochemistry of the
failing heart in vivo. Several reviews on microarrays in
cardiovascular diseases have been published (153,154). Var-
ious studies have identified differentially expressed genes
(155) and clustering gene expression profiles to find func-
tional groupings of genes (156).
The Writing Group’s review of several hundred reports
involving the use of EMB in cardiovascular disease also
revealed a number of clinically relevant and unanswered
questions. The utility of novel histological markers of inflam-
mation to define myocarditis and improve on the standard
Dallas criteria has only been explored in preliminary studies.
The sensitivity of EMB for viral-associated cardiomyopathy
is also a key unanswered question. Notably, the relative risks
and diagnostic yield of left versus right ventricular biopsy as
well as techniques to improve the safety of EMB have not
been investigated.
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